Basilea’s CEO Ronald Scott will retire. Chief Commercial Officer David Veitch named as successor. Changes in the Board of Directors
Basel, Switzerland, February 21, 2018 – Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that Chief Executive Officer Ronald Scott will retire after 18 years with the company. Basilea’s Board of Directors has appointed David Veitch, currently Basilea’s Chief Commercial Officer and member of the Management Committee, to succeed Mr. Scott in the role of Chief Executive Officer effective April 19, 2018.
Name: Ronald Scott
Company: Basilea Pharmaceutica Ltd.
Announcement Date: February 20, 2018, 11:00pm
Resignation Date: February 20, 2018, 11:00pm
Source 1: https://globenewswire.com/news-release/2018/02/21/1372305/0/en/Basilea-s-CEO-Ronald-Scott-will-retire-Chief-Commercial-Officer-David-Veitch-named-as-successor-Changes-in-the-Board-of-Directors.html